Japan-headquartered Daiichi Sankyo has established two research institutes- DS Research Institute Boston and DS Research Institute Munich, in Cambridge, Massachusetts, U.S. and Munich, Germany, respectively.

Daiichi Sankyo plans to initiate operations in both locations by September 2024 to build new, and deepen existing, partnerships in these world-renowned innovation hotspots toward the common goal of bringing medical innovation to patients.

By continued collaboration with other companies, universities, research institutions, and startups, Daiichi Sankyo aims to foster new innovative ideas and technologies as well company’s drug discovery function.

"The establishment of our research institutes in Cambridge and Munich marks an important step to solidify our presence in the global drug discovery ecosystem," said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “By enhancing our presence in these regions and utilizing our strengths in science and technology, Daiichi Sankyo will continuously generate innovation through further collaborations with business partners and academia, contributing to the enrichment of quality of life around the world.”